<?xml version="1.0" encoding="UTF-8"?>
<ref id="B54-pharmaceuticals-14-00381">
 <label>54.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Toniati</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Piva</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Cattalini</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Garrafa</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Regola</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Castelli</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Franceschini</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Air√≤</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Bazzani</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Beindorf</surname>
    <given-names>E.A.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy</article-title>
  <source>Autoimmun. Rev.</source>
  <year>2020</year>
  <volume>19</volume>
  <fpage>102568</fpage>
  <pub-id pub-id-type="doi">10.1016/j.autrev.2020.102568</pub-id>
  <pub-id pub-id-type="pmid">32376398</pub-id>
 </element-citation>
</ref>
